Improving Iron Status Without Iron: Clinical Insights From Recombinant Human Lactoferrin Supplementation
Abstract
Helaina human lactoferrin (LF) (effera®) is a potential, well-tolerated alternative for improving iron status in women who present with chronic iron deficiency. This case series reports on two active women who had persistently low iron levels and poor response to, or intolerance of, standard orally administered iron supplements. The two individuals independently started oral ingestion of effera® at 100 mg/day for 6-20 weeks. Both showed notable increases in ferritin, with one also exhibiting marked increases in serum iron and transferrin saturation. The two participants reported better energy, fewer symptoms, and improved exercise capacity, all without gastrointestinal issues. These results align with growing evidence that LF supports iron homeostasis through receptor-mediated absorption, hepcidin-ferroportin modulation, and immune-balancing effects, potentially surpassing or working in synergy with conventional treatments. While limited to case reports, these observations support further controlled trials of effera® as an adjunct or alternative for iron deficiency, including non-anemic presentations.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- OptiType: precision HLA typing from next-generation sequencing data
- Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications
- Saccharomyces cerevisiae cells have three Omega class glutathione S-transferases acting as 1-Cys thiol transferases
- Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.